ACTOS

This brand name is authorized in United States. It is also authorized in Australia, Austria, Croatia, Estonia, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug ACTOS contains one active pharmaceutical ingredient (API):

1
UNII JQT35NPK6C - PIOGLITAZONE HYDROCHLORIDE
 

Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.

 
Read more about Pioglitazone

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 ACTOS Tablet MPI, EU: SmPC European Medicines Agency (EU)
 ACTOS Tablet MPI, US: SPL/PLR FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
A10BG03 Pioglitazone A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BG Thiazolidinediones
Discover more medicines within A10BG03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
AU Pharmaceutical Benefits Scheme 8694N, 8695P, 8696Q
EE Ravimiamet 1013566, 1013577, 1013588, 1209372, 1209383, 1209394, 1209406, 1209417, 1209428, 1209439, 1212411, 1212422, 1212433, 1212444, 1212455, 1212466, 1212477, 1212488, 1212499, 1212501, 1212512, 1212523, 1212534, 1212545, 1494402, 1494413, 1494424, 1494435, 1494446, 1494457
ES Centro de información online de medicamentos de la AEMPS 00150001, 00150004, 00150004IP, 00150009, 00150010, 00150010IP
GB Medicines & Healthcare Products Regulatory Agency 140403, 140405, 161338, 175725, 175728, 178953, 180500, 198640, 20095, 20096, 374281, 374283, 374285, 51997
HK Department of Health Drug Office 47882, 47884
IE Health Products Regulatory Authority 10330, 10378, 10506, 10568, 10594, 10609, 10661, 10756, 10761, 10797, 10798, 15530, 15590
IL מִשְׂרַד הַבְּרִיאוּת 7091, 7092, 7093
IT Agenzia del Farmaco 034946018, 034946044, 034946121
JP 医薬品医療機器総合機構 3969007F1024, 3969007F2020, 3969007F3027, 3969007F4023
LT Valstybinė vaistų kontrolės tarnyba 1004071, 1004363, 1004508, 1026399, 1026400, 1026401, 1026402, 1026403, 1026404, 1026405, 1026406, 1026407, 1026408, 1026409, 1026410, 1026411, 1026412, 1026413, 1026414, 1026415, 1026416, 1026417, 1026418, 1026419, 1063617, 1063618, 1063619, 1063620, 1063621, 1063622
NL Z-Index G-Standaard, PRK 84247, 84255
PL Rejestru Produktów Leczniczych 100308456, 100308462, 100308479
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W08069001, W08069002, W08069003, W08069004, W08069005, W08069006, W08069007, W08069008, W08070001, W08070003, W08070004, W08070005, W08070006, W08070007, W08070008, W08070009, W08071001, W08071002, W08071003, W08071004, W08071005, W08071006, W08071007, W08071008
SG Health Sciences Authority 12441P, 12442P
TN Direction de la Pharmacie et du Médicament 5063311, 5063312
TR İlaç ve Tıbbi Cihaz Kurumu 8682758010016, 8682758010023
US FDA, National Drug Code 64764-151, 64764-301, 64764-451

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.